Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
May 11, 2023
Earnings Call Speaker Segments
Jennifer Good
executiveHello, everyone, and welcome to our call covering first-quarter results and a business update. Joining me is Lisa Delfini, Trevi's Chief Financial Officer. The two of us will share some prepared comments, and then we'll open things up for your questions. During the first quarter, we continued advancing the clinical development work for Haduvio in patients dealing with hard-to-treat chronic cough tied to idiopathic pulmonary fibrosis, or IPF, along with additional chronic cough indications and prurigo nodularis. Let me walk through where each program stands, beginning with our lead effort in chronic cough and IPF. IPF is a severe illness that occurs at the end of life, and the persistent coughing it brings is a leading cause of sickness that heavily affects how well a patient can live. There are no approved treatments for chronic cough and IPF, and this cough often fails to improve when patients try the therapies that have been tested against it. Individuals dealing with chronic cough and IPF might cough up to 1500 times per day, resulting in exhaustion, a feeling of not getting enough air, and heightened anxiety. There's also a theory that the ongoing cough seen in IPF may amplify the triggering of pro fibrotic mechanisms and make the disease worse. As we move into the next stage of development for our IPF chronic cough program, our plan is to conduct two studies at the same time. Starting off, there's a Phase 2b trial using various doses to determine the right range, and it will look at three different amounts of Haduvio along with a placebo. The specific strengths we're looking to test are 27, 54, and 108 milligrams BID. Our target is to enroll somewhere between 150 and 200 participants in total, and the treatment period is expected to run for roughly six weeks. Because we want to finish recruiting without delays, we plan to conduct this across several nations and locations. It's likely you're aware that there's a great deal of development activity happening with antifibrotics among IPF patients. Given that, we expect competition for participants, and we're taking that into account as we plan. The dose-ranging study's protocol is now complete, and we're preparing submissions to regulators in multiple countries; our CRO has been brought on board, and we're nearly done choosing countries and sites. Our aim is to launch that trial during this year's second half; alongside it, we're making plans for a Phase 1b study in respiratory physiology. A risk of respiratory depression is common to opioids as a class; across all our trials so far, our safety data haven't shown this, and some published literature indicates that mixed agonist antagonists demonstrate a ceiling effect when it comes to respiration's impact. That said, because IPF patients already have compromised breathing, we need to understand whether — and how much — the drug might suppress respiration in this group. Trevi intends to run a Phase 1b inpatient trial involving IPF patients who have a cough and whose disease severity varies, in order to find out whether any respiratory depression effects of clinical significance show up. Findings from this work will help us pin down who belongs in the population for our pivotal trial and, ultimately, in the label. We have received feedback from the FDA on the proposed Phase 1b study, and we are finalizing the protocol as we prepare to file the IND. Our expectation is to launch this study during the second half of this year too. Beyond what we are preparing in IPF cough, a protocol is also being developed for a Phase 2 trial in refractory chronic cough, or RCC. Since Haduvio acts both centrally within the brain and peripherally within the lungs, our belief is that it could deliver therapy across a variety of chronic cough indications no matter what disease lies underneath. This trial, we anticipate, will closely resemble the CANAL trial, a dose escalating crossover design, and roughly 60 subjects are expected to be enrolled. Many RCC trials have tested just a single mechanism, with one seeing some success — the P2X3s, which work peripherally in the lung mechanistically. Even so, we see a meaningful opportunity remaining for a mechanism acting both centrally and peripherally that might deliver strong, consistent efficacy in cough patients who are the hardest to treat; as we design our own study, we are drawing on what other companies learned in their earlier RCC development work. Attention for our cough data so far keeps building at upcoming medical conferences, with oral data presentations accepted at the American Thoracic Society meeting that starts at the end of next week, and at the American Cough Conference taking place in June. We've completed writing up the CANAL trial findings and have now sent that manuscript off for publication. From where I sit, this speaks to just how significant the unmet need is for these IPF patients who are so hard to treat, and it also shows the level of interest the medical community has in what we're doing across the cough space. Turning to Prurigo Nodularis, or PN: this is a severe and debilitating condition characterized by papules and nodules appearing on the skin, accompanied by intense itching. That's the additional indication where our efforts continue. Back in June of last year, we shared encouraging results from the Phase 2b/3 PRISM study in PN. On the primary endpoint, as well as every key secondary endpoint, the trial hit statistical significance. During Q1 2023, we wrapped up the 12-month open-label extension trial for PRISM. Analysis of the results from that trial is underway at this time. After that, our plan is to seek an end of Phase 2 meeting with the FDA, and we expect that meeting to take place sometime later in 2023. Following that meeting, we'll figure out what comes next for the program. Finally, we have underway a human abuse potential trial, something required for an NDA submission. Bear in mind that nalbuphine's injectable version currently carries no scheduling in the United States from the Drug Enforcement Agency, or DEA. For this particular study, the goal is to assess how much oral nalbuphine is liked—its abuse liability, in other words—against an active comparator, butorphanol. Butorphanol is a Schedule IV drug. We've broken the research into two parts; the first part is meant to characterize the various butorphanol doses and select one that performs well for comparison against oral nalbuphine in Part 2. Part 1 is complete at this point, and the butorphanol dose for the study's second phase has been selected. In that second phase, we're using a five-way crossover design that is randomized, double-blind, and controlled by both active and placebo treatments, and the aim there is to determine the abuse potential of three oral nalbuphine doses relative to the selected butorphanol dose and relative to placebo. Before we can proceed into Part 2, two gating criteria need to be satisfied. The first is a butorphanol shortage across the country; together with our CRO partner, we're working to obtain the doses required to run the study. The second is that we plan to send Part 1's results to the FDA so they can offer any feedback regarding the butorphanol dose selection prior to starting Part 2. If neither condition leads to a meaningful hold-up, we anticipate top line data from the human abuse potential study before this year ends. To wrap up, our attention is on execution so these studies can get underway; once each study begins, we'll make announcements and share further information about its design, anticipated timelines, and the very important trial name. I'll hand things over now to Lisa for a look at our financial results, and after that we'll take any questions you might have.
Lisa Delfini
executiveThanks, Jennifer, and good afternoon to all of you. You'll find the complete financial results for the quarter that closed on March 31, 2023 in the press release we put out before this call, as well as in our 10-Q, which we filed with the SEC today once the market had closed. During the first quarter of 2023, our net loss came to $6.4 million, versus a net loss of $7.3 million in the comparable quarter of 2022. R&D expenses totaled $5 million in the first quarter of 2023, up from $4.6 million in the same quarter of 2022. That rise was mainly driven by greater consulting and professional fees tied to start-up work for the three planned chronic cough trials. Partially offsetting this was a reduction in clinical development expenses, which reflects the fact that both the blinded portion of the Phase 2b/3 PRISM trial and the Phase 2 CANAL trial wrapped up in 2022. G&A expenses came in at $2.6 million in the first quarter of 2023, compared with $2.4 million in the same period of 2022. That increase was principally attributable to higher personnel-related expenses along with greater tax professional fees. Other income, net, was $1.2 million in the first quarter of 2023, compared with other expense, net, of $0.3 million in the same period of 2022. This shift was mainly the result of higher interest income. As of March 31, 2023, cash, cash equivalents and marketable securities together amounted to $111.3 million, down from $120.5 million as of December 31, 2022. After the first quarter ended, we chose to repay our term loan ahead of schedule. The sum paid was $6.5 million, which had been classified as current on our balance sheet because, under its terms, the final payment came due in the first quarter of 2024. That loan was held with Silicon Valley Bank, now a division of First Citizens Bank, and it carried restrictions requiring our corporate cash, cash equivalents and marketable securities to be kept at or managed by SVB. In light of what recently happened at SVB, we wanted to remove those restrictions. Our cash runway guidance is unchanged, since it had already factored in repayment of the note according to its terms. As a result, our cash, cash equivalents and marketable securities will allow us to fund our expenses into 2026. During the first quarter, we burned roughly $9 million of cash, which included finishing the clinical work on the PN open-label extension study and running Part 1 of the human abuse potential study. Setting aside the term note payoff, we anticipate cash burn of between $10 million to $12 million per quarter for the remainder of 2023 as we carry on the human abuse potential study and launch the IPF and RCC trials. That wraps up our prepared remarks. I'll now hand the call back to the operator for Q&A.
Analyst
analystHello. Stacy here, calling in on Annabel's behalf. Nice work on the quarter — we've got a handful of questions from our side. First off, what drove the choice to give doses reaching $162 million in the Phase 1b respiratory study in IPF, given that the Phase 2b doses are smaller? Also, has interest from outside groups in your RCC gone up a lot since GSK bought Bellus Health? And how has that shifted your strategic thinking about that indication?
Jennifer Good
executiveYeah. All right. Thanks for those, Stacy. Regarding the Phase 1b trial, the design isn't locked in yet. Right now we intend to administer only 108 milligrams. That said, this is among the topics that have been discussed back and forth with the FDA. So our view is that 108 is the only level we need, though we'll know more once it's finalized. On the RCC indication — sure, we received plenty of inbound interest; I realize I'm pointing out what's plain, but GSK definitely confirmed how significant cough is as a market and how much need remains unmet there. With refractory chronic cough too, I'd say there hasn't been much success. There are the two players with the P2X3, so from an investor standpoint things have stayed pretty active. We're already involved in many conversations about which — quite strategic ones, really — and I expect a number more across the coming two months at conferences. So yeah, I'd say it caught everyone's notice and definitely put the spotlight back on Trevi, since once Bellus was acquired, we were the lone stand-alone cough company; so that was positive for us.
Analyst
analystFantastic. Thanks a lot — that really helps.
Jennifer Good
executiveThanks, Stacy.
Serge Belanger
analystHello, and good afternoon. There's just one thing we wanted to ask about today. From what we understand, a new patent covering nalbuphine came through during the quarter. Could you bring us up to speed on where the product's intellectual property stands overall?
Jennifer Good
executiveSure, and thanks, Serge. That patent mattered a great deal to us, yes. A broad application has been submitted by us. That leaves us with three tiers of patent protection. First come the formulation patents that already exist for this product, and those begin lapsing around 2029. The main coverage extending past that point comes by way of method of treatment patents, and we've submitted a large, broad application covering a range of neurological coughs. Our approach was to use the data from the IPF CANAL trial and, in fact, extract claims and pursue a particular patent built on the dosing, the data, and so forth; that patent has now been granted. <<inaudible>> assisted us in that effort; in our view the claims in this patent are broad; it runs until 2039 and will be Orange Book listable. That really becomes the heart of the protection, in a sense. Beyond that, we've also submitted others, which we refer to as special population patents — information gathered in the hepatically impaired population and in the elderly, which will appear in the label regarding dosing; all of those still need to work their way through, yet should they be granted and actually make it into the label, protection would stretch out a further couple of years past that point. So securing that method of treatment in IPF chronic cough was extremely important to us.
Serge Belanger
analystThank you.
Jennifer Good
executiveYes. Thank you, Serge.
Analyst
analystHi. Matt Swanson here, standing in for Tom Smith. We've just got one brief item for you: what are the things holding up the start of a Phase 2 study in RCC along with the Phase 2b trial for chronic cough in IPF? Out of curiosity — you brought up a shortage of packaging material as one element — has that problem been resolved?
Jennifer Good
executiveYes. Let me make it plain: the supply problem I brought up concerns butorphanol and nothing else, and it impacts solely our human abuse potential study. It has no bearing on our Phase 2b dose ranging work or on our refractory chronic cough. For our own products, we hold ample drug supply. So to put it plainly, that stands as a separate matter on its own. Regarding what's holding us up at present — I walked you through a decent summary of everything we've completed; the real thing is obtaining sign-off from the regulatory agencies. These trials are being conducted across multiple countries. That means we must deal with feedback from the different regulators; even so, our protocols are final and will go in for regulatory input, and honestly that's the decisive element — we stated we'd begin during this year's second half. If the regulatory path goes fairly smoothly, it happens earlier, and should any comments come back, we'd need to revise the protocol and return to them, which could push it somewhat later within the second half.
Analyst
analystGot it. Thank you.
Jennifer Good
executiveYou are welcome.
Analyst
analystHello, this is William <<inaudible>> speaking instead of Mayank. Great job on the excellent quarter, and we appreciate you answering our question. We have a few things to ask. At the regulatory stage, I suppose, might you refresh our memory regarding the present IND situation for Haduvio in chronic cough and what kind of progress is being made?
Jennifer Good
executiveThanks, William. Sure, so we have been receiving feedback from the FDA concerning the Phase 1b respiratory physiology study. That is going to serve as our study for opening the IND. So we are getting it ready at this time, and it ought to be filed with the agency before long. However, luckily, there has been plenty of productive conversation with them regarding the program, so we ought to be in a position to push it through and, with any luck, have the IND opened and keep that study advancing.
Analyst
analystUnderstood, that's really useful. Now when we look at RCC, regarding the group of patients you intend to go after, will you cast the net widely and include everyone, or lean toward focusing on particular subsets where you believe Haduvio has the greatest chance of succeeding and then expand outward from those, or perhaps some mix of the two? Could you give us your thoughts on that?
Jennifer Good
executiveYes. That's a fair question, and this ties back to something I brought up earlier. We don't have to reinvent the wheel here. A great deal of research has already been conducted in RCC. It has turned out to be fairly evident that using an enrichment approach in that setting works well; so we're still ironing out the specifics, though most likely we'll adopt a 2:1 enrichment approach for coughers above 20 along with a certain share of coughers falling within the 10 to 19 bracket. We do need to stay careful, however, since BELLLUS is currently conducting those 2 pivotal trials using this greater than 20 enrichment criterion. Should we fail to include that as a requirement in our own trials, we would wind up with only the mild coughers. That outcome isn't something we want. Therefore we've built in certain parameters to achieve a more enriched population, yet we will still examine some of the lower coughers, something they are also doing. Their approach uses a 3:1 randomization.
Analyst
analystUnderstood, that tracks. Then just a final quick item. I'm aware you said the open-label prism data is being reviewed, and that a meeting with the FDA is coming. Is there any signal or detail about the timing and venue where that might surface? Also, have there been any possible interactions related to that, or involving that program?
Jennifer Good
executiveYes. So William, honestly I'm still waiting to see those results for myself; the physician on our side who's pushing that forward is in the process of pulling it together, and then we'll bring it to the team. As for where it ends up being presented, the most clear next major derm conference, in my view, is EADV, taking place in Europe during the fall. That said, we'll likely include some of the top line findings in one of our press releases, since I know people have interest in it. On the strategic discussions side, we remain active on that front and keep pushing them forward. However, as we've stated, we also want to hold our end of Phase 2 meeting, so that we can pin down precisely what remains in this program; so we've definitely been engaged in conversations. We're aware of the short list of interest. I believe it comes down to getting through that FDA meeting and then reevaluating at that stage in light of what we find out.
Analyst
analystUnderstood. That covers everything on our end. Thanks once more for fielding our questions. And congrats again on the strong quarter. Appreciate it.
Jennifer Good
executiveThanks.
Sean Kim
analystHello there, and thanks for fielding my questions. First, regarding the nodularis program: what type of response are you anticipating from the close of the Phase 2 meeting that would allow you to proceed with that program? Then my second inquiry concerns the RCC area. Given that BELLLUS Health is now being purchased by GSK, the bigger pharma company, has that altered your perspective about possibly commercializing Haduvio yourselves by directing commercial operations within the U.S., or perhaps forming a partnership to take on the larger biopharmas? Thanks.
Jennifer Good
executiveThank you, Sean. Regarding PN, in terms of the response, the crucial item we need to verify is whether the Phase 2b/3 counts as one of our two pivotal trials—whether the agency concurs that just one further trial is required. We will submit the protocol for that upcoming trial, which is basically identical to the one we recently completed, perhaps somewhat longer. So we simply need confirmation that a single additional study is needed. This is how it appears. There are a few minor CMC matters to resolve, though nothing significant. It is genuinely quite—everything really centers on that, that we are essentially there. Concerning RCC, I do not believe our perspective has shifted whatsoever. I think we keep refining internally where we intend to compete. And I think the way the RCC market works out for us is that we are targeting the severe, difficult-to-treat patients. P2X3s are effective in roughly half the population and ineffective in roughly half the population, and we attribute that to their acting on that peripheral chain. We think that owing to our central mechanism, we ought to be able to help a greater number of patients and deliver a larger effect. Thus our lead indication will be IPF chronic cough, which we believe positions us for favorable premium pricing, plus other interstitial lung diseases. We think we might sustain that at a fairly robust level for capturing the failures within the chronic cough market, which represents approximately half of that market. So it remains a substantial opportunity. That is our way of thinking about it. Regarding partnering it out, we tell partners whenever they bring that up: we are a single asset company and cough is our primary focus; therefore, if someone wants the U.S. rights for that program, they will need to acquire Trevi. We will consider Japan or perhaps Europe, but within the U.S., they will simply have to purchase the company.
Sean Kim
analystAlright, thanks. That’s useful. Thank you so much.
Jennifer Good
executiveYes, thank you, Sean.
Annabel Samimy
analystMy apologies for that. The question we had has already been addressed. Thanks.
Jennifer Good
executiveWe'd like to express our gratitude to everyone who joined us on today's call. Before summer is in full swing, there are a number of conferences and medical meetings coming up that we'll be taking part in. Those are listed in the earnings release we put out today. I'm looking forward to running into some of you at those meetings. Thank you.
Operator
operatorThat wraps up this conference call. We appreciate you joining us for today's presentation, and you're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.